The cell therapy human raw materials market size has grown rapidly in recent years. It will grow from $2.82 billion in 2024 to $3.36 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, high demand for regenerative medicines, governmental funding and support, and growing healthcare expenditure.
The cell therapy human raw materials market size is expected to see rapid growth in the next few years. It will grow to $6.67 billion in 2029 at a compound annual growth rate (CAGR) of 18.7%. The growth in the forecast period can be attributed to expanding therapeutic applications, rising patient awareness, favorable regulatory frameworks, a growing biopharmaceutical sector, and improved manufacturing processes. Major trends in the forecast period include the adoption of allogeneic therapies, the integration of artificial intelligence, an increase in off-the-shelf cell therapies, the use of 3D bioprinting technology, and the and the development of hybrid cell therapies.
The forecast of 18.7% growth over the next five years reflects a modest reduction of 1.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. gene therapy developers by driving up costs of human-derived growth factors and cytokines imported from the UK and Netherlands, exacerbating cell therapy production expenses and increasing orphan drug development burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing adoption of regenerative medicine is expected to propel the cell therapy human raw materials market in the coming years. Regenerative medicine aims to repair, replace, or regenerate damaged tissues and organs by utilizing the body’s inherent regenerative abilities or external methods such as stem cells, tissue engineering, or gene therapy, all with the goal of restoring normal function. The increased prominence of regenerative medicine is driven by advancements in biotechnology, a better understanding of cellular mechanisms, the rising demand for personalized medicine, and its potential to address previously unmet medical needs. Cell therapy and human raw materials play a crucial role in this progress by supplying the necessary biological components for cell-based therapies, which are essential for creating standardized and reliable treatments for various health conditions. For example, a report from the Alliance for Regenerative Medicine, a US-based non-profit, revealed that in Q1 2023, there were 2,760 cell, gene, and tissue-engineering therapeutic developers globally, marking a 101% increase from 1,369 in Q1 2022. As a result, the increasing adoption of regenerative medicine is fueling the growth of the cell therapy human raw materials market.
Leading companies in the cell therapy human raw materials market are increasingly focusing on the development of chemically defined cell culture media to expedite cell therapy development. A cell culture medium is a nutrient-rich solution designed to furnish essential nutrients, growth factors, and environmental conditions necessary for the in vitro growth and propagation of cells outside their natural environment. For example, in May 2023, Lonza Group AG, a Switzerland-based healthcare manufacturing organization, introduced the TheraPEAK T-VIVO Cell Culture Medium, featuring a chemically defined formulation, serum-free and animal component-free composition, recombinant proteins, enhanced culture and expansion support, and application assistance, ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium represents significant technological advancements by eliminating animal components, adopting a chemically defined formulation, and incorporating regulatory-friendly characteristics, thereby contributing to improved safety, quality, and regulatory compliance.
In January 2022, Thermo Fisher Scientific Inc., a US-based scientific research and laboratory services company, completed the acquisition of PeproTech Inc. for $1.85 billion. This strategic acquisition expands Thermo Fisher's recombinant protein portfolio, aligns with its biosciences business, and strengthens its market position, impacting the cell therapy human raw materials market by enhancing product offerings and market capabilities. PeproTech Inc. is a US-based biotechnology company specializing in manufacturing products for life science research, including cytokines, antibodies, and cell culture media.
Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.
North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell therapy human raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cell therapy human raw materials market consists of sales of primary cells, stem cell banks, tissue scaffolds, cryopreservation media, cell separation products, and extracellular matrices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The cell therapy human raw materials market research report is one of a series of new reports that provides cell therapy human raw materials market statistics, including cell therapy human raw materials industry global market size, regional shares, competitors with an cell therapy human raw materials market share, detailed cell therapy human raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy human raw materials industry. This cell therapy human raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell therapy human raw materials encompass biological substances derived from human sources, including cells, tissues, and blood components, utilized as foundational elements in the development and manufacturing of cell-based therapeutic products. These raw materials play crucial roles in various stages of cell therapy production aimed at creating treatments for diseases such as cancer, genetic disorders, and degenerative conditions.
The primary product types of cell therapy human raw materials include cell culture media, cell culture serum, cell culture supplements, reagents and buffers, and others. Cell culture media are solutions designed to provide nutrients and an optimal environment for cell growth outside their natural setting, which is essential for laboratory-based cell studies. These products find application in various types of cell therapies, including dendritic cell therapy, natural killer (NK) cell therapy, stem cell therapy, and T-cell therapy. End users encompass biopharmaceutical and pharmaceutical companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), as well as academic and research institutions.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell therapy human raw materials market size is expected to see rapid growth in the next few years. It will grow to $6.67 billion in 2029 at a compound annual growth rate (CAGR) of 18.7%. The growth in the forecast period can be attributed to expanding therapeutic applications, rising patient awareness, favorable regulatory frameworks, a growing biopharmaceutical sector, and improved manufacturing processes. Major trends in the forecast period include the adoption of allogeneic therapies, the integration of artificial intelligence, an increase in off-the-shelf cell therapies, the use of 3D bioprinting technology, and the and the development of hybrid cell therapies.
The forecast of 18.7% growth over the next five years reflects a modest reduction of 1.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. gene therapy developers by driving up costs of human-derived growth factors and cytokines imported from the UK and Netherlands, exacerbating cell therapy production expenses and increasing orphan drug development burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing adoption of regenerative medicine is expected to propel the cell therapy human raw materials market in the coming years. Regenerative medicine aims to repair, replace, or regenerate damaged tissues and organs by utilizing the body’s inherent regenerative abilities or external methods such as stem cells, tissue engineering, or gene therapy, all with the goal of restoring normal function. The increased prominence of regenerative medicine is driven by advancements in biotechnology, a better understanding of cellular mechanisms, the rising demand for personalized medicine, and its potential to address previously unmet medical needs. Cell therapy and human raw materials play a crucial role in this progress by supplying the necessary biological components for cell-based therapies, which are essential for creating standardized and reliable treatments for various health conditions. For example, a report from the Alliance for Regenerative Medicine, a US-based non-profit, revealed that in Q1 2023, there were 2,760 cell, gene, and tissue-engineering therapeutic developers globally, marking a 101% increase from 1,369 in Q1 2022. As a result, the increasing adoption of regenerative medicine is fueling the growth of the cell therapy human raw materials market.
Leading companies in the cell therapy human raw materials market are increasingly focusing on the development of chemically defined cell culture media to expedite cell therapy development. A cell culture medium is a nutrient-rich solution designed to furnish essential nutrients, growth factors, and environmental conditions necessary for the in vitro growth and propagation of cells outside their natural environment. For example, in May 2023, Lonza Group AG, a Switzerland-based healthcare manufacturing organization, introduced the TheraPEAK T-VIVO Cell Culture Medium, featuring a chemically defined formulation, serum-free and animal component-free composition, recombinant proteins, enhanced culture and expansion support, and application assistance, ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium represents significant technological advancements by eliminating animal components, adopting a chemically defined formulation, and incorporating regulatory-friendly characteristics, thereby contributing to improved safety, quality, and regulatory compliance.
In January 2022, Thermo Fisher Scientific Inc., a US-based scientific research and laboratory services company, completed the acquisition of PeproTech Inc. for $1.85 billion. This strategic acquisition expands Thermo Fisher's recombinant protein portfolio, aligns with its biosciences business, and strengthens its market position, impacting the cell therapy human raw materials market by enhancing product offerings and market capabilities. PeproTech Inc. is a US-based biotechnology company specializing in manufacturing products for life science research, including cytokines, antibodies, and cell culture media.
Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.
North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell therapy human raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cell therapy human raw materials market consists of sales of primary cells, stem cell banks, tissue scaffolds, cryopreservation media, cell separation products, and extracellular matrices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The cell therapy human raw materials market research report is one of a series of new reports that provides cell therapy human raw materials market statistics, including cell therapy human raw materials industry global market size, regional shares, competitors with an cell therapy human raw materials market share, detailed cell therapy human raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy human raw materials industry. This cell therapy human raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell therapy human raw materials encompass biological substances derived from human sources, including cells, tissues, and blood components, utilized as foundational elements in the development and manufacturing of cell-based therapeutic products. These raw materials play crucial roles in various stages of cell therapy production aimed at creating treatments for diseases such as cancer, genetic disorders, and degenerative conditions.
The primary product types of cell therapy human raw materials include cell culture media, cell culture serum, cell culture supplements, reagents and buffers, and others. Cell culture media are solutions designed to provide nutrients and an optimal environment for cell growth outside their natural setting, which is essential for laboratory-based cell studies. These products find application in various types of cell therapies, including dendritic cell therapy, natural killer (NK) cell therapy, stem cell therapy, and T-cell therapy. End users encompass biopharmaceutical and pharmaceutical companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), as well as academic and research institutions.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary2. Cell Therapy Human Raw Materials Market Characteristics3. Cell Therapy Human Raw Materials Market Trends and Strategies32. Global Cell Therapy Human Raw Materials Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Cell Therapy Human Raw Materials Market34. Recent Developments in the Cell Therapy Human Raw Materials Market
4. Cell Therapy Human Raw Materials Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, and Covid and Recovery on the Market
5. Global Cell Therapy Human Raw Materials Growth Analysis and Strategic Analysis Framework
6. Cell Therapy Human Raw Materials Market Segmentation
7. Cell Therapy Human Raw Materials Market Regional and Country Analysis
8. Asia-Pacific Cell Therapy Human Raw Materials Market
9. China Cell Therapy Human Raw Materials Market
10. India Cell Therapy Human Raw Materials Market
11. Japan Cell Therapy Human Raw Materials Market
12. Australia Cell Therapy Human Raw Materials Market
13. Indonesia Cell Therapy Human Raw Materials Market
14. South Korea Cell Therapy Human Raw Materials Market
15. Western Europe Cell Therapy Human Raw Materials Market
16. UK Cell Therapy Human Raw Materials Market
17. Germany Cell Therapy Human Raw Materials Market
18. France Cell Therapy Human Raw Materials Market
19. Italy Cell Therapy Human Raw Materials Market
20. Spain Cell Therapy Human Raw Materials Market
21. Eastern Europe Cell Therapy Human Raw Materials Market
22. Russia Cell Therapy Human Raw Materials Market
23. North America Cell Therapy Human Raw Materials Market
24. USA Cell Therapy Human Raw Materials Market
25. Canada Cell Therapy Human Raw Materials Market
26. South America Cell Therapy Human Raw Materials Market
27. Brazil Cell Therapy Human Raw Materials Market
28. Middle East Cell Therapy Human Raw Materials Market
29. Africa Cell Therapy Human Raw Materials Market
30. Cell Therapy Human Raw Materials Market Competitive Landscape and Company Profiles
31. Cell Therapy Human Raw Materials Market Other Major and Innovative Companies
35. Cell Therapy Human Raw Materials Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cell Therapy Human Raw Materials Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cell therapy human raw materials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell therapy human raw materials? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell therapy human raw materials market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Cell Culture Media; Cell Culture Sera; Cell Culture Supplements; Reagents and Buffers; Other Raw Materials2) By Type of Cell Therapy: Dendritic Cell Therapy; Natural Killer (NK) Cell Therapy; Stem Cell Therapy; T-Cell Therapy
3) By End-Use: Biopharmaceutical and Pharmaceutical Companies; Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs); Academic and Research Institutions
Subsegments:
1) By Cell Culture Media: Serum-Free Media; Serum-Based Media; Defined Media; Specialized Media (E.G., For Stem Cells)2) By Cell Culture Sera: Fetal Bovine Serum (FBS); Human Serum; Adult Bovine Serum
3) By Cell Culture Supplements: Growth Factors; Cytokines; Peptides
4) By Reagents and Buffers: Enzymes (E.G., Trypsin); Ph Buffers; Cryoprotectants
5) By Other Raw Materials: Cell-Free DNA; Plasma and Platelet-Rich Plasma (PRP); Vials and Storage Containers
Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; GE Healthcare; Corning Incorporated; Lonza Group Ltd.; Grifols S.A.; WuXi AppTec; Catalent Inc.; Sartorius AG; Charles River Laboratories; Bio-Rad Laboratories Inc.; Pall Corporation; Bio-Techne Corporation; Miltenyi Biotec; Actylis; STEMCELL Technologies; Takara Bio Inc.; Vericel Corporation; ACROBiosystems; BioIVT LLC; Orgenesis Inc.; PromoCell GMBH; ViaCyte Inc.; AllCells LLC; Sartorius CellGenix GmbH; Fujifilm Cellular Dynamics Inc.; Mesoblast Limited; RoosterBio Inc.; Thermogenesis Holdings Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Cell Therapy Human Raw Materials market report include:- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Merck KGaA
- GE Healthcare
- Corning Incorporated
- Lonza Group Ltd.
- Grifols S.A.
- WuXi AppTec
- Catalent Inc.
- Sartorius AG
- Charles River Laboratories
- Bio-Rad Laboratories Inc.
- Pall Corporation
- Bio-Techne Corporation
- Miltenyi Biotec
- Actylis
- STEMCELL Technologies
- Takara Bio Inc.
- Vericel Corporation
- ACROBiosystems
- BioIVT LLC
- Orgenesis Inc.
- PromoCell GMBH
- ViaCyte Inc.
- AllCells LLC
- Sartorius CellGenix GmbH
- Fujifilm Cellular Dynamics Inc.
- Mesoblast Limited
- RoosterBio Inc.
- Thermogenesis Holdings Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | September 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.36 Billion |
| Forecasted Market Value ( USD | $ 6.67 Billion |
| Compound Annual Growth Rate | 18.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
